Novo Nordisk A/SBagsværd Denmark
Key Novo Nordisk A/S Financials
| Company Type | Public -(NYSE: NVO) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Sales (mil.) | $11,982.1 |
| 2011 Employees | 32,000 |
Try a Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Limit your risk
Check your customers' credit with
D&B Credit Reports
Novo Nordisk A/S Income Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Revenue | 11,982.1 | 10,812.1 | 9,837.6 |
| Cost of Goods Sold | 2,273.6 | 2,077.9 | 2,010.4 |
| Gross Profit | 9,708.5 | 8,734.2 | 7,827.3 |
| Gross Profit Margin | 81% | 80.8% | 79.6% |
| SG&A Expense | 4,018.2 | 3,782.2 | 3,502.2 |
| Depreciation & Amortization | -- | 438.9 | 491.3 |
| Operating Income | 4,040.7 | 3,360.7 | 2,876.1 |
| Operating Margin | 33.7% | 31.1% | 29.2% |
| Nonoperating Income | (0.7) | 190.4 | (10.6) |
| Nonoperating Expenses | (80.4) | (298.0) | (171.4) |
| Income Before Taxes | 3,959.7 | 3,253.1 | 2,694.1 |
| Income Taxes | 871.9 | 690.8 | 620.2 |
| Net Income After Taxes | 3,087.7 | 2,562.3 | 2,073.9 |
| Continuing Operations | 3,087.7 | 2,562.3 | 2,073.9 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 3,087.7 | 2,562.3 | 2,073.9 |
| Total Net Income | 3,087.7 | 2,562.3 | 2,073.9 |
| Net Profit Margin | 25.8% | 23.7% | 21.1% |
| Diluted EPS from Total Net Income | 5.42 | 4.38 | 3.43 |
| Dividends per Share | 1.29 | 0.96 | 0.84 |
All amounts in millions of US Dollars except per share amounts.
Novo Nordisk A/S Balance Sheet
| Assets | Dec 11 | Dec 10 | Dec 09 |
| Current Assets | |||
| Cash | 2,421.5 | 2,137.8 | 2,175.6 |
| Net Receivables | 2,277.0 | 1,627.8 | 1,514.2 |
| Inventories | 1,703.6 | 1,723.7 | 1,929.1 |
| Other Current Assets | 748.0 | 1,145.1 | 672.6 |
| Total Current Assets | 7,150.1 | 6,634.4 | 6,291.5 |
| Net Fixed Assets | 3,780.1 | 3,648.2 | 3,702.9 |
| Other Noncurrent Assets | 754.2 | 640.8 | 548.9 |
| Total Assets | 11,684.5 | 10,923.4 | 10,543.3 |
| Liabilities | Dec 11 | Dec 10 | Dec 09 |
| Current Liabilities | |||
| Accounts Payable | 594.4 | 517.0 | 431.8 |
| Short-Term Debt | 63.4 | 306.0 | 80.5 |
| Other Current Liabilities | 3,094.9 | 2,463.9 | 2,071.4 |
| Total Current Liabilities | 3,752.7 | 3,286.9 | 2,583.7 |
| Long-Term Debt | 90.7 | 89.7 | 186.8 |
| Other Noncurrent Liabilities | 1,078.0 | 970.8 | 890.4 |
| Total Liabilities | 4,921.4 | 4,347.3 | 3,660.9 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 6,763.1 | 6,576.1 | 6,882.4 |
| Total Equity | 6,763.1 | 6,576.1 | 6,882.4 |
| Shares Outstanding (thou.) | 580,000.0 | 600,000.0 | 620,000.0 |
All amounts in millions of US Dollars except per share amounts.
Novo Nordisk A/S Cash Flow Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Net Operating Cash Flow | 3,860 | 3,501 | 2,962 |
| Net Investing Cash Flow | (624.7) | (992.5) | (586.7) |
| Net Financing Cash Flow | (3,034.4) | (2,351.8) | (1,934.7) |
| Net Change in Cash | 201.0 | 156.6 | 444.5 |
| Depreciation & Amortization | 438.9 | 491.3 | |
| Capital Expenditures | (601.8) | (693.3) | (590.3) |
| Cash Dividends Paid | (1,029.4) | (782.8) |
All amounts in millions of US Dollars except per share amounts.